胚胎植入前遗传学检测 中国就医指南

Preimplantation Genetic Testing (PGT) is a specialized laboratory procedure performed during in vitro fertilization (IVF) to analyze embryos for genetic abnormalities prior to uterine transfer. It is not a disease but a diagnostic and preventive reproductive technology used within reproductive medicine to enhance the likelihood of a healthy pregnancy and reduce the risk of transmitting inheritable genetic disorders. PGT encompasses three primary subtypes: PGT-A (aneuploidy screening), which detects abnormal chromosome numbers (e.g., trisomy 21); PGT-M (monogenic/single-gene disorders), which identifies specific pathogenic variants linked to conditions such as cystic fibrosis, spinal muscular atrophy, or Huntington’s disease; and PGT-SR (structural rearrangements), designed for carriers of balanced chromosomal translocations or inversions. Pathogenesis underlying the need for PGT lies in gametogenesis errors—especially maternal meiotic nondisjunction—and de novo or inherited germline mutations. These errors increase with advancing maternal age, particularly after 35, and are also associated with recurrent pregnancy loss, repeated IVF implantation failure, severe male factor infertility, and known familial monogenic disease carriers. Epidemiologically, aneuploidy affects ~30–60% of human blastocysts, rising sharply with maternal age; approximately 1 in 200 live births carries a clinically significant monogenic disorder, and ~0.5–1% of couples undergoing IVF have an indication for PGT-M or PGT-SR. Key risk factors include advanced maternal age (>35 years), parental balanced chromosomal rearrangements, prior child or pregnancy affected by a genetic condition, history of ≥2 unexplained miscarriages, and multiple failed IVF cycles. While PGT itself carries no direct physical symptoms or morbidity, its clinical context profoundly impacts quality of life: patients often experience significant emotional distress—including anxiety, grief, guilt, and decisional burden—related to fertility challenges, ethical dilemmas around embryo selection/discard, financial strain, and prolonged treatment timelines. Psychosocial support, genetic counseling, and shared decision-making are integral to mitigating these impacts. Importantly, PGT does not guarantee pregnancy or eliminate all genetic risks—it cannot detect polygenic disorders, mosaicism below detection thresholds, or de novo mutations occurring post-biopsy. Its success depends on IVF efficacy, embryology expertise, and comprehensive pretest genetic counseling to define appropriate indications, limitations, and alternatives.

# 胚胎植入前遗传学检测（PGT）治疗方案与费用明细

一、非手术/保守方案（适用于单基因病、染色体结构异常携带者、反复种植失败等）

• •PGT-A（非整倍体筛查）：含促排卵监测、取卵、ICSI、囊胚培养、活检、高通量测序（NGS）、胚胎冷冻及解冻移植；费用区间：38,000–52,000元
• •PGT-M（单基因病诊断）：含家系分析、探针定制（1–2万元）、NGS检测；费用区间：55,000–78,000元
• •PGT-SR（染色体结构重排）：含核型验证、断点定位、NGS检测；费用区间：62,000–85,000元
• •*含基础检查费*（AMH、染色体核型、病原体筛查、精液分析等）：2,800–4,500元

二、手术/微创介入方案

• •胚胎活检（必需核心步骤）：显微操作下滋养层细胞活检（≤5细胞），属辅助生殖技术关键环节，无独立手术收费，已含于上述PGT套餐；术前必查：宫腔镜评估（如怀疑内膜异常）2,200–3,600元

三、特殊复杂方案

• •多病种联合检测（如PGT-M+PGT-A）、嵌合体胚胎再分析、三代测序验证：+12,000–25,000元
• •反复活检失败或低获卵者加用微刺激方案/卵巢储备改善治疗（DHEA、生长激素等）：+3,000–8,000元

四、方案快速选择指南

• •预算有限/首次尝试：优选PGT-A（4万级）；
• •明确单基因病家族史：必选PGT-M（6万级起）；
• •平衡成本与精准度：PGT-SR+NGS全覆盖（7万级）；
• •既往多次失败/高龄（≥40岁）：建议PGT-A联合ERA/EMMA内膜容受性检测（总约6.5万元）。